Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis

BACKGROUND: Systemic mastocytosis is a clonal myeloproliferative neoplasm associated with constitutional symptoms from mast cell mediated chemical and cytokine release. According to the literature, Ruxolitinib, a JAK1/JAK2 inhibitor, has been shown to reduce symptoms related to proinflammatory cytok...

Descripción completa

Detalles Bibliográficos
Autores principales: Yacoub, Abdulraheem, Prochaska, Lindsey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743131/
https://www.ncbi.nlm.nih.gov/pubmed/26855781
http://dx.doi.org/10.1186/s40364-016-0056-5
_version_ 1782414303668731904
author Yacoub, Abdulraheem
Prochaska, Lindsey
author_facet Yacoub, Abdulraheem
Prochaska, Lindsey
author_sort Yacoub, Abdulraheem
collection PubMed
description BACKGROUND: Systemic mastocytosis is a clonal myeloproliferative neoplasm associated with constitutional symptoms from mast cell mediated chemical and cytokine release. According to the literature, Ruxolitinib, a JAK1/JAK2 inhibitor, has been shown to reduce symptoms related to proinflammatory cytokine release in other myeloproliferative neoplasms. CASE PRESENTATION: Here we present a case using Ruxolitinib for disabling constitutional symptoms despite complete bone marrow response in a patient with aggressive systemic mastocytosis. Assessment tools used to monitor symptoms in previously published Ruxolitinib trials were adopted to track symptom improvement and quality of life. CONCLUSIONS: Ruxolitinib significantly improved symptoms and quality of life in our patient with systemic mastocytosis.
format Online
Article
Text
id pubmed-4743131
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47431312016-02-06 Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis Yacoub, Abdulraheem Prochaska, Lindsey Biomark Res Case Report BACKGROUND: Systemic mastocytosis is a clonal myeloproliferative neoplasm associated with constitutional symptoms from mast cell mediated chemical and cytokine release. According to the literature, Ruxolitinib, a JAK1/JAK2 inhibitor, has been shown to reduce symptoms related to proinflammatory cytokine release in other myeloproliferative neoplasms. CASE PRESENTATION: Here we present a case using Ruxolitinib for disabling constitutional symptoms despite complete bone marrow response in a patient with aggressive systemic mastocytosis. Assessment tools used to monitor symptoms in previously published Ruxolitinib trials were adopted to track symptom improvement and quality of life. CONCLUSIONS: Ruxolitinib significantly improved symptoms and quality of life in our patient with systemic mastocytosis. BioMed Central 2016-02-05 /pmc/articles/PMC4743131/ /pubmed/26855781 http://dx.doi.org/10.1186/s40364-016-0056-5 Text en © Yacoub and Prochaska. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Yacoub, Abdulraheem
Prochaska, Lindsey
Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis
title Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis
title_full Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis
title_fullStr Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis
title_full_unstemmed Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis
title_short Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis
title_sort ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743131/
https://www.ncbi.nlm.nih.gov/pubmed/26855781
http://dx.doi.org/10.1186/s40364-016-0056-5
work_keys_str_mv AT yacoubabdulraheem ruxolitinibimprovessymptomsandqualityoflifeinapatientwithsystemicmastocytosis
AT prochaskalindsey ruxolitinibimprovessymptomsandqualityoflifeinapatientwithsystemicmastocytosis

Ejemplares similares